RA Capital, a prominent biotech investor, is targeting a Chinese biotechnology company for merger with its latest special purpose acquisition company (SPAC), according to a securities filing. The move represents the firm's continued expansion into international biotech markets through its SPAC vehicle strategy.
The securities filing indicates RA Capital's intention to identify and merge with a Chinese biotech firm, though specific target companies or therapeutic areas have not been disclosed. This approach allows the investment firm to bring private Chinese biotech companies to public markets through the SPAC structure.